Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.

Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. by Castanheira M, Deshpande LM, Messer SA, Rhomberg PR and Pfaller MA published in Int. J. Antimicrob. Agents. in press, 2019.

In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018.

In vitro activity of minocycline against U.S. isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. by Flamm RK, Shortridge D, Castanheira M, Sader HS and Pfaller MA. published in Antimicrob. Agents. Chemother. 63 (11): e01154, 2019.

The Infectious Diseases Society of America’s 10 x ’20 Initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): Is 20 x ’20 a possibility?

The Infectious Diseases Society of America’s 10 x ’20 Initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): Is 20 x ’20 a possibility? by Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW and Infectious Diseases Society of A. published in Clin. Infect. Dis. 2019; 69 (1): 1-11

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. by Sader HS, Mendes RE, Pfaller MA and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (5): 1306-1310

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program.

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK published in J. Glob. Antimicrob. Resist.: in press, 2019.

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017

Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017. Lead author: IA Critchley, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #1465

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States

In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia: SENTRY Surveillance 2017-2018 Results from the United States. Lead author: S Paukner, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster # 703

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Lefamulin Dose Justification and Susceptibility Breakpoint Determinations for Patients With Community-Acquired Bacterial Pneumonia

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Lefamulin Dose Justification and Susceptibility Breakpoint Determinations for Patients With Community-Acquired Bacterial Pneumonia. Lead author: SM Bhavnani, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster #19

Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program

Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program. Lead author: S Paukner, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # T-74

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA)

In Vitro Activity of the β-lactamase Inhibitor QPX7728 In Combination with Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA). Lead author: M Castanheira, presented at ID Week 2019, October 2-6, Washington, DC, USA
Poster #681